Celgene Corp. announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, including patients with cytogenetic features of high-risk disease, who were previously treated with ibrutinib.
FDA has cleared the first at-home self-collection kit for HPV screening, removing significant obstacles to cervical cancer detection.
